Sachs Associates would like to say we enjoyed hosting a virtual conference and thank those who participated in our Sachs Spring Life Sciences Week, which incorporated the 2nd Annual European HealthTech CEO Forum (EHTF) and the 14th Annual European Life Sciences CEO Forum (ELSF). A special thank you goes to the excellent line up of sponsors, chairpersons, panelists and presenters who made such a broad and interesting programme possible. The virtual conference is proving successful in supporting our community with 525 people from 29 countries registered, over 10,000 messages sent, and nearly 1300 meetings completed during the Sachs Spring Life Sciences Week. We look forward to seeing you in our future events !
CONFIRMED KEYNOTE SPEAKERS INCLUDED:
Keynote: “EIT Health Accelerator: How we facilitate expertise and investment opportunities in the European healthcare sector” by Kurt Höller, Director of Business Creation, EIT Health e.V.
Big Pharma Fireside Chat with Nigel Sheail, Global Head of M&A and BD&L, Novartis International AG, moderated by Jeffrey Bockman, EVP, Head of Oncology Practice, Cello Health BioConsulting.
Introductory Speech by Sandra Ferri, Head of Life Sciences, European Investment Fund
Keynote: “How China is Transforming the Clinical Development Landscape & the Biopharma Industry” By John Oyler, Co-Founder, Chairman & CEO, BeiGene Ltd.
SPEAKERS & CHAIRS INCLUDED:
Adam Kostyál, SVP of the Global Listing Services & Head of European Listings, Nasdaq
Andreas Hohn, Director of Transaction Excellence, Roche Partnering, F. Hoffmann-La Roche Ltd.
Anker Lundemose, CEO, Mission Therapeutics Ltd
Aram Mangasarian, CEO, NOXXON Pharma NV
Ashish Patel, Principal, Optum Ventures
Bibhash Mukhopadhyay, Principal, New Enterprise Associates (NEA)
Carlos de Sousa, CEO, Ultimovacs ASA
Carlos Buesa, Founder & CEO, Oryzon Genomics S.A.
Chris Maggos, Managing Director, Head of Europe, LifeSci Advisors
Christophe Bourrilly, Head of Healthcare, Oddo BHF co-chair for European Capital Markets Panel
Corinne Venot, Senior Director, Business Development, BeiGene Ltd.
Tim Haines, Chairman & Managing Partner, Abingworth
Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist R&D Global Search & Evaluation, Novo Nordisk A/S
Wesley Holmes, Partner, Latham & Watkins LLP
Yochi Slonim, Co-Founder & CEO, Anima Biotech, Inc.
Zhihong Chen, President & CEO, Curon Biopharmaceutical
FINANCIAL, ADVISORY, INVESTORS ATTENDING:
3B Future Health Fund (formerly Helsinn Investment Fund) 3B Future Health Ventures Sarl (Helsinn Investment Fund) 3E Bioventures 4BIO Capital AbbVie Deutschland GmbH Co. KG AbbVie Ventures Abingworth LLP ACXIT Capital Management GmbH Additio Investment Group Advent Life Sciences aescuvest international GmbH Aglaia Oncology Funds Aisling Capital LLC ALSA Ventures Altitude Investment Management Andera Partners Aqua Partners LLC ARCH Venture Partners Arix Bioscience Plc. ARTO AG Asabys Partners To View All - Click Here